目的:比较伴或不伴高脂血症的系统性红斑狼疮(SLE)患者的狼疮性肝损害的构成比例,了解高脂血症与狼疮性肝损害的相关性。方法:收集SLE患者100例,根据高脂血症和狼疮性肝损害的诊断标准,将患者分为高脂血症组,非高脂血症组和肝损害组,非肝损害组,收集其相关临床数据进行比较分析。结果:1高脂血症组发生肝损害的比例高于非高脂血症组(χ2=9.908,P=0.002);2血脂水平中甘油三酯与γGT(r=0366,P=0.000),碱性磷酸酶(r=0.241,P=0.018),强的松剂量(r=0.31,P=0.006),24h尿蛋白定量(r=0.273,P=0.007)相关;TC与24h尿蛋白定量(r=0.273,P=0.007)相关;HDL与γ谷氨酸转肽酶(r=0.233,P=0.022),碱性磷酸酶(r=0.265,P=0.009)相关;3-SLE活动组出现高脂血症的比例高于非活动组(χ2=6.986,P=0.008)。结论:长期的高脂血症可导致或加重SLE患者肝功能损害,高脂血症是狼疮性肝损害的危险因素之一。
Citation:
LI Min,YANG Min,CEN Xiaomin,et al.. Analysis for Hyperlipemia Correlation with Hepatic Involvement in Systemic Lupus Erythematosus. West China Medical Journal, 2009, 24(8): 2060-2062. doi:
Copy
Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
1. |
BORBA E F, BONFA E, VINAGRE C G, et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus[J]. Arthritis Rheum,2000,43:1033-1038.
|
2. |
王丽英,张葳.系统性红斑狼疮与脂代谢异常[J].中华风湿病学杂志,2004,8(8):496-499..
|
3. |
贺巧玲.系统性红斑狼疮血管炎患者血浆组织因子途经抑制物的测定与意义[J].中国现代医学杂志,1999,9(7):29.
|
4. |
MFILLER M H, UROWITZ M B, GLADMAN D D, et al. The liver in system lupus erythematosus[J]. Q J Med,1984,211:401-409..
|
5. |
BOMBARDIER C, G LANDMAN D D, UROWITZ M B, et al. Derivation of the SLEDAI a disease activity index for lupus patients. The Committee on Prognosis in SLE[J]. Arthritis Rheum,1992,35:630-640.
|
6. |
沈霞,高峰,陈肖燕.调查研究脂肪肝的诱发因素[J].上海医学检验杂志,1999,14(4):236.
|
7. |
许韩师,叶任高,纪玉莲,等.狼疮性肝损害的临床和免疫学特点(附32例临床分析)[J].中国现代医学杂志,2000,10(1):4-5..
|
8. |
王吉耀.脂肪肝流行病普查[J].中华肝脏病杂志,2000,8(2):117-119..
|
9. |
BORBA E F, BONFA E. Dyslipop roteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolip in antibodies[J]. Lupus,1997,6(6):553-559.
|
- 1. BORBA E F, BONFA E, VINAGRE C G, et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus[J]. Arthritis Rheum,2000,43:1033-1038.
- 2. 王丽英,张葳.系统性红斑狼疮与脂代谢异常[J].中华风湿病学杂志,2004,8(8):496-499..
- 3. 贺巧玲.系统性红斑狼疮血管炎患者血浆组织因子途经抑制物的测定与意义[J].中国现代医学杂志,1999,9(7):29.
- 4. MFILLER M H, UROWITZ M B, GLADMAN D D, et al. The liver in system lupus erythematosus[J]. Q J Med,1984,211:401-409..
- 5. BOMBARDIER C, G LANDMAN D D, UROWITZ M B, et al. Derivation of the SLEDAI a disease activity index for lupus patients. The Committee on Prognosis in SLE[J]. Arthritis Rheum,1992,35:630-640.
- 6. 沈霞,高峰,陈肖燕.调查研究脂肪肝的诱发因素[J].上海医学检验杂志,1999,14(4):236.
- 7. 许韩师,叶任高,纪玉莲,等.狼疮性肝损害的临床和免疫学特点(附32例临床分析)[J].中国现代医学杂志,2000,10(1):4-5..
- 8. 王吉耀.脂肪肝流行病普查[J].中华肝脏病杂志,2000,8(2):117-119..
- 9. BORBA E F, BONFA E. Dyslipop roteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolip in antibodies[J]. Lupus,1997,6(6):553-559.